Retatrutide
Also searched as: LY3437943 · triple agonist
Retatrutide is an investigational molecule targeting three receptors: GIP, GLP-1 and glucagon. It is in clinical trials and is not approved anywhere in the world. That is the single most important fact about it: unlike semaglutide and tirzepatide, its trial programme has not concluded and its long-term safety profile is not established.
What the research has looked at
- Phase 2 trials in obesity and type 2 diabetes
- Ongoing Phase 3 programme
- Comparative effect against dual and single agonists
This is a description of what has been studied, not a claim about what it does. Evidence level: early human data.
Legal position in the UK
Not a licensed medicine in the UKNot licensed anywhere. It is an investigational medicinal product. There is no lawful route to it outside a clinical trial, and material sold online as retatrutide carries no assurance of identity, purity or sterility.
Handling and storage
Not applicable to any lawfully obtained product, since the only legitimate supply is within a trial where it is handled by the study site.
Vial sizes: Not lawfully supplied to individuals. Where a manufacturer supplies handling instructions, those take precedence over anything general.
Questions
- Is retatrutide approved?
- No. It is in clinical trials and is not approved in the UK, the EU, the United States or anywhere else. Its trial programme has not concluded.
- Why do so many sites sell it then?
- Because there is demand ahead of approval. Anything sold outside a trial is unlicensed, and the buyer has no way to verify what is actually in the vial. That is the position, stated plainly.